Ablation of ventricular tachycardia in 2021

Stefano Bianchi¹* and Filippo Maria Cauti²

¹UOC Cardiologia, Ospedale Fatebenefratelli Isola Tiberina, Roma, Italy; and
²Unità di Aritmologia Cardiaca, Ospedale Fatebenefratelli Isola Tiberina, Roma, Italy

Nowadays, ablation of ventricular tachycardia (VT) in structural heart disease is an increasingly used procedure. In fact, it is the most effective strategy in controlling arrhythmic burden in VT patients. The ablative approaches are the result of the last 10 years of technological advances (Catheters, 3D mapping systems) and the constant study of the pathophysiological mechanisms underlying arrhythmic circuits. This presentation seeks to revisit the state of the art in the ablative treatment of VT.

Catheter ablation is currently considered the most effective non-pharmacological approach in reducing recurrence of ventricular tachycardia (VT).¹ Several randomized trials (SMASH VT, VTACH, VANISH) have evaluated and demonstrated the efficacy of the ablative technique in VT with ischaemic substrate.² To date, the guidelines recommend as Class I indication ablation in patients with sustained ventricular arrhythmia and ischaemic substrate after failure of drug therapy.³ Optimal timing with which to act is also the subject of study. In fact, clinical outcomes appear to be better the earlier the treatment.⁴ Just as the absolute urgency in the ablative treatment of patients with electrical storm is an established fact.⁵

The ablative strategy as well as the effectiveness of the ablation itself is closely related to the substrate under examination. The ablation of VT in patients with post-ischaemic dilated heart disease has a significantly better outcome than that of patients with non-ischaemic dilated cardiomyopathy.⁶

However, it is necessary to specify that this ‘crude’ subdivision (ischaemic VT/non-ischaemic VT) does not take into consideration the variety of non-ischaemic substrates: idiopathic dilated cardiomyopathy, arrhythmogenic cardiomyopathy, cardiac sarcoidosis, channelopathies, valvular heart disease, and congenital heart disease.

If we take this further subdivision into consideration, ablative efficacy shows a wide variability.

The ablative strategy involves the use of three-dimensional navigation systems that allow not only non-fluoroscopic navigation (which can be magnetic/electric/dielectric or hybrid) of the different leads inside the heart chambers and epicardium but also an electrical characterization of the substrate under consideration.⁹

In recent years, the use of high-density mapping catheters has revolutionized the way of mapping ventricular arrhythmias, making VT ablation no longer a prerogative of high-volume centres.

The procedure is now faster, safer, and more effective. The countless space-time information acquired simultaneously by high-density mapping catheters has allowed a more accurate study of the pathophysiological mechanisms underlying the arrhythmic circuits both in animal models and in humans.

This assumption completely changed the procedural endpoints.

The first radiofrequency approaches in fact took their cue from the surgical approach in which the diseased area was ‘resected’. The functional study of the substrate in fact allowed the transition from a coarse ablation aimed at the ‘abolition’ of the scar (substrate homogenization) to a more selective and elegant ablation.

In recent years, two pioneering mapping methods heavily dependent on the analysis of the functional substrate have been introduced and have shown very encouraging results.¹⁰,¹¹ Tung et al. introduced the isochronal late activation map capable of defining zones of deceleration (DZ) during sinus rhythm acquisition. The deceleration zones have a strong
correlation with the critical isthmus during tachycardia and it is for this reason that the targeted ablation of these DZs determines a drastic reduction in arrhythmic relapses in the follow-up.

Similarly, our group demonstrated additional ablative targets based on the ventricular electrogram duration map (VEDUM). The VEDUM map is in fact able to outline a discrete area of long-lasting potentials which during VT identifies the vulnerable punctual region of the critical isthmus and in sinus rhythm the area of possible arrhythmogenic circuits.

The mapping/ablation methods are therefore varied but cannot be separated from an accurate analysis of the substrate in sinus rhythm/pacing/atrial fibrillation (substrate mapping) and when possible during VT (activation mapping).

Whichever intra-procedural endpoint is used, numerous studies have shown that non-inducibility at the end of the procedure remains the gold standard.

Despite technological advances and numerous pathological studies, the long-term ablative outcome is still frustrating. This is due not only to poor knowledge of the substrate but also sometimes to the difficulty in reaching the area of interest.

Radiofrequency catheters have evolved over the years, also becoming safer and more effective in creating the lesion. The depth of the lesion is a function of the intra-tissue temperature reached, in turn correlated to various factors such as pressure, local impedance, temperature, and power.

The impossibility of reaching some intramural ablative targets has created the conditions for the development of new techniques such as the application of an ablation electro-catheter lead with a needle at the tip (needle catheter), which allows to penetrate the thickness of the myocardial wall, the application of radiofrequency with a bipolar circuit, the use of high impedance, and low tonic irrigation solutions (half normal saline).

Cardiac imaging

Pre-procedural imaging (CT/CMR) integrated with navigation systems has been established since the early 2000s. Obtaining an imaging before the procedure is undoubtedly extremely useful to define a priori the localization and some details of the substrate in question.

Two software have been introduced on the market (ADAS VT and MUSIC) for the characterization of the intrinsic properties of the myocardium. Object of study is their use to guide ablative procedures.

New frontiers

The neuro-autonomic target

The sympathetic nervous system plays a key role in the genesis of ventricular arrhythmias. Sympathetic cardiac denervation performed with classic (T1–T4) or modified (T2–T4) methods demonstrated a significant reduction in arrhythmic events after ablative failure. Renal denervation also demonstrated an additional role in controlling arrhythmic burden in cases of failure of standard methods.

New minimally invasive approaches

Cuculich et al. introduced the use of stereotaxic radiotherapy to non-invasive treatment of the substrate responsible for the arrhythmic genesis in the VT panorama.

Conflict of interest: none declared.

References

1. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, Aguinaga L, Leite LR, Al-Khatib SM, Anter E, Berruezo A, Callans DJ, Chung MK, Cuculich P, d’Avila A, Deal BJ, Deja Bella P, Denekic T, Dickfeld T-M, Hadid C, Haqgani HM, Kay GM, Latchamsetty R, Marchlinski F, Miller JM, Nogami A, Patel AR, Pathak RK, Saenz Morales LC, Santangeli P, Sapp JL, Sarkozy A, Soejima K, Stevenson WG, Tedrow UB, Tzou WS, Varma N, Zeppenfeld K. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm 2020;17:e2-e159.
2. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, Kralovec S, Sediva L, Ruskin JN, Josephson ME. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007;357:2657–2665.
3. Kuck K-H, Schaumann A, Eckardt S, Willems S, Ventura R, Delacretaz E, Piltscher H-F, Kautzner J, Schumacher B, Hansen PS. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375:31-40.
4. Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin J-F, Thibault B, Rivard L, Gula L, Leong-Sit R, Essebag V, Nery PB, Tung SK, Raymond J-M, Sterns LD, Veinheuyzen GD, Healey JS, Redfearn D, Roux J-F, Tang ASL. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 2016;375:111-121.
5. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hatkay MA, Jagor LA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018;72:e91-e220.
6. Romero J, Di Biase L, Diaz JC, Quispe R, Du X, Brinceno D, Avendano R, Tedrow U, John RM, Michaud GF, Natalie A, Stevenson WG, Kumar S. Early versus late referral for catheter ablation of ventricular tachycardia in patients with structural heart disease: a systematic review and meta-analysis of clinical outcomes. JACC Clin Electrophysiol 2018;4:374-382.
7. Piori SG, Blomstrom-Lundqvist C. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmies and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Pediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793-2867.
8. Kumar S, Romero J, Mehta NK, Fuji i A, Kapur S, Baldinger SH, Barbhaiya CR, Koplan BA, John RM, Epstein LM, Michaud GF, Tedrow UB, Stevenson WG. Long-term outcomes after catheter ablation of ventricular tachycardia in patients with and without structural heart disease. Heart Rhythm 2016;13:1957-1963.
9. Kim Y-H, Chen S-A, Ernst S, Guzman CE, Han S, Kalarus Z, Labadet C, Lin Y-J, Lo L-W, Nagami A, Saad EB, Sapp J, Sticherling C, Tilz R, Tung R, Kim YG, Stiles MK. 2019 APHRS expert consensus statement on three-dimensional mapping systems for tachycardia developed in collaboration with HRS, EHRA, and LAHRS. J Arrhythm 2020;36:215-270.
10. Raiman M, Tung R. Automated isochronal late activation mapping to identify deceleration zones: rationale and methodology of a practical electroanatomic mapping approach for ventricular tachycardia ablation. Comput Biol Med 2018;102:336-340.
11. Rossi P, Cauti FM, Nicolina M, Calore F, Fanti V, Polselli M, Di Pastena A, Iaia L, Bianchi S. A novel Ventricular map of Electrograms Duration as a Method to identify areas of slow conduction for ventricular tachycardia ablation: the VEDUM pilot study. *Heart Rhythm* 2021;18:1253–1260.

12. Stevenson WG, Tedrow UB, Reddy V, AbdelWahab A, Dukkipati S, John RM, Fujii A, Schaeffer B, Tanigawa S, Elsokkari I, Koruth J, Nakamura T, Niamiwakar A, Ghidoli D, Pellegrini C, Sapp JL. Infusion needle radiofrequency ablation for treatment of refractory ventricular arrhythmias. *J Am Coll Cardiol* 2019;73:1413–1425.

13. Della Bella P, Peretto G, Paglino G, Bisciglia C, Radinovic A, Sala S, Baratto F, Limite LR, Cireddu M, Marzi A, D’Angelo G, Vergara P, Gulletta S, Mazzone P, Frontera A. Bipolar radiofrequency ablation for ventricular tachycardias originating from the interventricular septum: safety and efficacy in a pilot cohort study. *Heart Rhythm* 2020;17:2111–2118.

14. Nguyen DT, Tzou WS, Sandhu A, Gianni C, Anter E, Tung R, Valderrábano M, Hranitzky P, Soeijma K, Saenz L, Garcia FC, Tedrow UB, Miller JM, Gerstenfeld EP, Burkhardt JD, Natale A, Sauer WH. Prospective multicenter experience with cooled radiofrequency ablation using high impedance irrigant to target deep myocardial substrate refractory to standard ablation. *JACC Clin Electrophysiol* 2018;4:1176–1185.

15. Roca-Luque I, Van Breukelen A, Alarcon F, Garre P, Tolosana JM, Borras R, Sanchez P, Zaraket F, Doltra A, Ortiz-Perez JT, Prat-Gonzalez S, Perea RJ, Guasch E, Arbelo E, Beruezo A, Sitges M, Brugada J, Mont L. Ventricular scar channel entrances identified by new wideband cardiac magnetic resonance sequence to guide ventricular tachycardia ablation in patients with cardiac defibrillators. *Europace* 2020;22:598–606.

16. Yamashita S, Sacher F, Mahida S, Berte B, Lim HS, Komatsu Y, Amraoui S, Denis A, Derval N, Laurent F, Sermeant M, Montaudon M, Hocini M, Haïssaguerre M, Jais P, Cochet H. Image integration to guide catheter ablation in scar-related ventricular tachycardia. *J Cardiovasc Electrophysiol* 2016;27:699–708.

17. Cauti FM, Rossi P, Sommer P. The sympathetic nervous system and ventricular arrhythmias: an inseparable union. *Eur Heart J* 2021;ehab168. doi:10.1093/eurheartj/ehab168.

18. Vaseghi M, Barwad P, Corrales FJM, Tandri H, Mathuria N, Shah R, Sorg JM, Gima J, Mandal K, Sáenz Morales LC, Lokhandwala Y, Shivkumar K. Cardiac sympathetic denervation for refractory ventricular arrhythmias. *J Am Coll Cardiol* 2017;69:3070–3080.

19. Cauti FM, Rossi P, Bianchi S, Bruno K, Iaia L, Rossi C, Pugliese F, Quaglione R, Venuta F, Anile M. Outcome of a modified sympatheticotomy for cardiac neuromodulation of untreatable ventricular tachycardia. *JACC Clin Electrophysiol* 2021;7:442–449.

20. Cuculich PS, Schill MR, Kashani R, Mutic S, Lang A, Cooper D, Faddis M, Gleva M, Noheria A, Smith TW, Hallahan D, Rudy Y, Robinson CG. Noninvasive cardiac radiation for ablation of ventricular tachycardia. *N Engl J Med* 2017;377:2325–2336.